Navigating the FDA Regulatory Pathway for Companion Diagnostics

Introduction: The Importance of FDA Approval for Companion Diagnostics

Companion diagnostics (CDx) are essential tools that identify which patients are likely to benefit from a specific therapeutic product. In the United States, the U.S. Food and Drug Administration (FDA) regulates CDx as in vitro diagnostic (IVD) devices under the Federal Food, Drug, and Cosmetic Act (FDCA). For a CDx to be marketed, especially when it is required for the safe and effective use of a corresponding therapeutic product, it must undergo a rigorous FDA review and approval process.

This tutorial article explains the step-by-step FDA approval pathway for companion diagnostics, from pre-submission meetings to post-market responsibilities, with regulatory citations, examples, and real-world applications.

Step 1: Understanding Device Classification and Regulatory Pathways

Most companion diagnostics are classified as Class III medical devices, which typically require Premarket Approval (PMA). In some cases, if a CDx has a similar predicate device, a 510(k) submission may apply. However, for CDx associated with new drugs, the PMA is the default route.

Key Regulations:

• 21 CFR Part 809 (In Vitro Diagnostic Products)
• 21 CFR Part 814 (Premarket Approval of Medical Devices)
• FDA Guidance: In Vitro Companion Diagnostic Devices (2014, updated 2020)

Example: The cobas® EGFR Mutation Test v2 received PMA approval as a companion diagnostic for osimertinib.

Step 2: Early Engagement – Q-Submissions and Pre-Submission Meetings

The Q-submission program allows developers to seek FDA feedback before submitting a formal application. Pre-submission meetings help clarify regulatory expectations, analytical validation needs, and labeling considerations.

• Types of Q-Subs: Pre-Sub, IDE, PMA, IND, Breakthrough Designation
• Key Content: Intended use, proposed indication, study design, predicate devices, risk analysis

Tip: Submit questions 60–75 days prior to your proposed meeting date. Expect written feedback within 70–90 days.

Visit FDA’s Q-submission program page for details.

Step 3: Analytical and Clinical Validation

Analytical validation ensures the CDx consistently and accurately detects the biomarker of interest. FDA expects robust performance metrics, including:

• Limit of Detection (LOD) and Limit of Quantification (LOQ)
• Precision (inter- and intra-assay CVs)
• Specificity and cross-reactivity testing
• Stability (sample and reagent)
• Reproducibility across sites/operators

For clinical validation, developers often conduct a bridging study alongside the therapeutic trial. The goal is to demonstrate that the diagnostic accurately identifies populations benefiting from the drug.

Example: PD-L1 IHC 22C3 pharmDx was validated using tumor samples from the KEYNOTE-010 and KEYNOTE-024 studies for pembrolizumab indication.

Step 4: IDE Submission for Trials Using Investigational CDx

If a CDx is used in a clinical trial to determine patient eligibility, and it is not yet FDA-approved, an Investigational Device Exemption (IDE) may be required. IDEs apply if:

• The CDx is used to make therapeutic decisions (i.e., significant risk)
• The diagnostic data supports the therapeutic’s efficacy or safety

IDE approval is essential when the CDx is pivotal to trial enrollment. Otherwise, retrospective testing with stored samples may be used to support submission.

Step 5: Premarket Approval (PMA) Submission Requirements

PMA submissions are comprehensive and include:

• Device description and manufacturing details
• Analytical and clinical performance data
• Labeling and instructions for use (IFU)
• Human factors testing
• Quality system and design controls (21 CFR 820)

PMA review timeline: ~180 days (excluding clock stops). The review includes potential Advisory Committee meetings for high-profile CDx.

Step 6: Labeling and Therapeutic Drug Coordination

CDx labeling must clearly specify the intended use population, biomarker criteria, and compatible platforms. FDA expects harmonized labeling between the drug and its CDx.

Key Labeling Elements:

• Intended Use Statement: “The [device] is intended to identify patients with [biomarker] for treatment with [drug name]”
• Performance Characteristics: Sensitivity, specificity, precision
• Platform compatibility and limitations
• Sample type and handling

Co-approval of CDx and therapeutic product ensures aligned launch strategies, especially under NDA or BLA submissions. CDx labeling must be cross-referenced in the drug’s package insert.

Step 7: FDA Approval and Post-Market Responsibilities

Once approved, the CDx manufacturer must adhere to post-market surveillance and compliance obligations, including:

• Medical Device Reporting (MDR) of adverse events
• Design change controls
• Annual reports to FDA
• Post-approval studies (if required)
• Lot release and product traceability

Real-world performance data may also be requested to confirm continued effectiveness in diverse populations.

Bridging Studies and Retrospective Validation Approaches

When simultaneous therapeutic and CDx development isn’t feasible, retrospective analysis is acceptable under FDA’s bridging guidance. Stored tissue samples can be tested with the proposed CDx after the drug trial concludes.

Bridging Study Elements:

• Sample selection and integrity verification
• Parallel testing with new and reference assay
• Positive and negative percent agreement (PPA/NPA)

This strategy has been used effectively in oncology where fresh samples are often limited.

Case Study: CDx Approval for Osimertinib

In 2015, the FDA approved osimertinib (Tagrisso) along with the cobas EGFR Mutation Test v2. Key points:

• Drug: Osimertinib for T790M-positive NSCLC
• CDx: cobas EGFR Mutation Test v2
• Sample type: Plasma ctDNA and FFPE tissue
• PMA submitted: with clinical trial data from AURA3 study
• Turnaround time: ~10 months

This marked the first approval of a liquid biopsy CDx for a targeted therapy.

Tips for Successful FDA CDx Submission

• Engage early with the FDA via Q-submissions
• Align clinical and diagnostic development timelines
• Ensure rigorous analytical validation across sample types
• Pre-plan co-labeling language and drug-CDx launch strategies
• Use checklists from FDA’s CDRH Device Advice portal

Refer to CDx co-development framework at ICH Q14 for international alignment.

Conclusion

Obtaining FDA approval for a companion diagnostic is a structured but complex process. It requires scientific rigor, early regulatory engagement, and precise coordination with therapeutic product development. From analytical validation to PMA submission and post-market vigilance, each step ensures that the CDx is reliable, reproducible, and critical for patient safety. A well-executed FDA approval strategy positions both the diagnostic and the drug for commercial success and clinical impact.

Distinguishing Analytical and Clinical Validation in Biomarker Qualification

Why Understanding Both Validation Types is Essential

Biomarkers are powerful tools in precision medicine, but before they can be qualified for regulatory use, they must undergo rigorous validation. This validation process is bifurcated into two critical arms: analytical validation and clinical validation. Understanding the difference is not just academic—it’s central to meeting global regulatory expectations from authorities like the FDA, EMA, and PMDA.

Analytical validation ensures that the biomarker assay performs reliably under laboratory conditions, while clinical validation confirms the association between the biomarker and the intended clinical outcome. Both must align with the defined Context of Use (COU) submitted in biomarker qualification programs.

As outlined by the FDA’s BEST Resource (Biomarkers, EndpointS, and other Tools), the distinct roles of analytical and clinical validation are pivotal in determining whether a biomarker can inform decision-making in clinical trials and drug development.

Defining Analytical Validation

Analytical validation focuses on confirming that a biomarker test or assay measures what it is intended to, in a consistent, accurate, and precise manner. It is typically performed in a controlled laboratory setting using reference standards and validated procedures.

Key Parameters in Analytical Validation:

• Specificity: Ability to measure the intended analyte without interference
• Sensitivity: Minimum detectable concentration (LOD)
• Limit of Detection (LOD) and Limit of Quantification (LOQ): Lower bounds of reliable detection and quantitation
• Precision: Reproducibility of results across replicates (intra- and inter-assay variability)
• Accuracy: Closeness of test results to the actual concentration
• Linearity and Range: Ability to produce proportional results over expected concentrations
• Stability: Biomarker integrity across sample handling, freeze-thaw cycles, and storage

Example: An ELISA-based assay for measuring Neuron Specific Enolase (NSE) might demonstrate an intra-assay CV% of <10%, LOQ of 0.5 ng/mL, and linearity from 0.5–100 ng/mL to pass analytical validation.

What is Clinical Validation?

While analytical validation ensures laboratory assay performance, clinical validation confirms the biomarker’s ability to correlate with a clinically meaningful endpoint or condition. This step often involves evaluating the biomarker across populations, conditions, or interventions to prove relevance and utility.

Core Aspects of Clinical Validation:

• Association with Disease State: Can the biomarker distinguish between diseased and non-diseased individuals?
• Correlation with Clinical Outcome: Is there a strong predictive or prognostic link?
• Reproducibility: Are findings consistent across independent studies?
• Sensitivity & Specificity: Key diagnostic metrics based on clinical datasets
• Population Diversity: Validation across age, ethnicity, disease stages, etc.
• Biological Plausibility: Mechanistic understanding enhances credibility

Case Example: Plasma pTau-217 has shown strong clinical validation in Alzheimer’s disease through multi-cohort studies linking levels to amyloid PET positivity and future cognitive decline.

Regulatory Expectations and Global Harmonization

Both analytical and clinical validation are non-negotiable for regulatory qualification. Agencies like the FDA and EMA have specific expectations documented in their qualification guidelines.

See also: PharmaValidation: ICH-compliant Templates for Biomarker Validation

Bridging the Gap Between Analytical and Clinical Validation

Although distinct, analytical and clinical validations are interdependent. A biomarker may demonstrate strong clinical relevance but fail regulatory qualification if its assay shows poor precision or matrix interference. Conversely, analytically robust biomarkers that lack disease correlation are not clinically useful.

Bridging the gap involves:

• Aligning validation studies with the defined COU
• Using standardized assay protocols across clinical sites
• Collecting both lab performance data and clinical outcome measures in parallel
• Establishing robust audit trails (ALCOA+ compliance) across validation phases

Dummy Workflow:

Common Pitfalls and How to Avoid Them

Biomarker programs often stall due to misaligned validation strategies. Some frequent issues include:

• Inconsistent sample collection affecting assay reproducibility
• Underpowered clinical studies that yield weak correlations
• Use of research-use-only (RUO) assays in validation studies
• Lack of early regulatory consultation for COU alignment

Best practices involve cross-functional planning, involving regulatory affairs, biostatistics, and assay developers from early phases. Pre-submission meetings with FDA or EMA can clarify expectations.

Case Study: Cardiac Troponin Biomarkers

The validation of high-sensitivity cardiac troponin (hs-cTnI) as a diagnostic marker for acute myocardial infarction is a classic case of harmonized analytical and clinical validation:

• Analytical Validation: Standardized assays with CV% <10% at 99th percentile
• Clinical Validation: Multi-center trials confirming elevated levels predict infarction
• Outcome: Included in FDA-approved diagnostic panels and clinical practice guidelines

This success was facilitated by global harmonization efforts like the IFCC Task Force on Clinical Applications of Cardiac Biomarkers.

Emerging Trends in Biomarker Validation

Validation approaches are evolving in response to new biomarker modalities and data science capabilities:

• Digital biomarkers: Require new metrics for device and algorithm validation
• AI-driven biomarkers: Explainability and performance on real-world data are key validation targets
• Real-world evidence (RWE): Being increasingly accepted for clinical validation
• Decentralized Trials: Require robust protocols for remote sample and data collection

Resources like WHO Digital Health Guidelines provide frameworks for validation in low-resource settings.

Conclusion

Analytical and clinical validation form the backbone of biomarker qualification. While analytical validation ensures assay reliability, clinical validation determines its true relevance in patient care and drug development. Regulatory bodies worldwide require a transparent, data-rich, and harmonized approach to both. By integrating both validation tracks early in biomarker programs, sponsors and researchers can significantly accelerate regulatory acceptance and real-world application of novel biomarkers.